Calcitonin intranasal - Novartis

Drug Profile

Calcitonin intranasal - Novartis

Alternative Names: Miacalcin Nasal Spray; Miacalcin® intranasal; Salcatonin intranasal - Novartis

Latest Information Update: 01 Aug 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Novogyne Pharmaceuticals
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 20 Jul 2012 The European Medicines Agency recommended that intranasal calcitonin-containing medicines should not be used for osteoporosis. Due to an increased risk of cancer associated with long-term use, calcitonin medicines should only be used for the shortest possible time using the minimum effective dose .
  • 03 Dec 2002 The CPMP has recommended approval of intranasal calcitonin for treatment of established post-menopausal osteoporosis throughout the European Union
  • 31 Dec 2001 Launched for Postmenopausal osteoporosis treatment in Austria (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top